Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies

Abstract

T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment with T-cell engagers is cytokine release syndrome (CRS), which is a potentially life-threatening condition characterized by release of inflammatory mediators. The treatment of CRS is similar to that of other hyper-inflammatory conditions and involves supportive treatment as well as immunosuppressive therapy. The risk of CRS can be mitigated by step-up dosing and immunosuppressive pre-treatment, as argued in this review.

Bidragets oversatte titelNot Available
OriginalsprogDansk
ArtikelnummerV08230544
TidsskriftUgeskrift for Laeger
Vol/bind186
Udgave nummer9
ISSN0041-5782
DOI
StatusUdgivet - 26 feb. 2024

Emneord

  • Humans
  • Receptors, Chimeric Antigen
  • Cytokine Release Syndrome
  • Antineoplastic Agents
  • Immunotherapy
  • Immunosuppressive Agents/adverse effects

Fingeraftryk

Dyk ned i forskningsemnerne om 'Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies'. Sammen danner de et unikt fingeraftryk.

Citationsformater